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Infectious Diseases Unit, Red Cross General Hospital, Athens, GreeceA B S T R A C TObjective: HIV infection is currently regarded as a global chronic
disease. The purpose of this study was to assess the direct cost of
illness per patient per year in Greece.Methods: A retrospective study for
the estimation of the direct cost of HIV infection was performed from
the third-party payer perspective. Data from 447 patients monitored in a
general hospital of Athens were collected from their medical records.
The survey involved all services and treatments that patients (stratiﬁed
into three health states according to the number of CD4 cells/ml as
deﬁned by the Centers for Disease Control and Prevention classiﬁcation
system for HIV infection) received in 1 year, as well as demographic data.
Results: The annual direct cost per patient was calculated at €6859 
€4699. Antiretroviral therapy cost was estimated at €5741, while the
annual cost of providing health care services regardless of health state
was computed at €1118, with laboratory investigation and imaging
studies representing €924 (13.5%), outpatient visits €34 (0.5%), andee front matter Copyright & 2014, International S
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. 11521, Athens, Greece.hospitalization €160 (2.3%) of total cost, respectively. Overall, direct cost
per patient was found to increase as the CD4 T lymphocytes decreased,
leading to prolonged hospitalization and an increase in the number of
laboratory tests. Direct cost for patients with more than 500 CD4 cells/μl
was estimated at €6067, whereas for those with 200 to 499 cells/μl and
less than 200 cells/μl, it was assessed at €6857 and €7654, respectively.
Conclusions: The direct cost of HIV infection per patient increased as
CD4 T lymphocytes decreased. The largest part of expenses was
attributed to antiretroviral therapy, followed by laboratory tests/imaging
studies, hospitalization, and ﬁnally outpatient visits.
Keywords: antiretroviral therapy, cost of illness, direct cost, health care
services, HIV infection.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The ﬁrst cases of HIV infection were reported in the early 1980s in
the United States . As was later discovered, however, the virus
appeared several decades earlier and was transmitted to humans
by Pan troglodytes troglodytes, a chimpanzee species [1,2]. The
HIV infection has captured since then the interest of researchers
who bestir themselves in the ﬁeld of medicine, social sciences,
and health economics because its complex pathology affects all
these sectors.
Since the 1980s, the transmission of the virus resulted in rapid
and fatal spread within a relatively short time. As soon as the
virus is transmitted through sexual ﬂuids, blood, or breast milk, it
enters host cells with speciﬁc mechanisms and starts the repli-
cation of the genetic material, resulting in continuous prolifer-
ation. Antiretroviral drugs interfere in different stages of the virus
life cycle by preventing multiplication. The nonadministration of
antiretroviral agents engenders faster disease progression, and
ﬁnally patient’s end of life because of a drop in the immune
system [3,4].Effective disease management represents a challenge for
practitioners, as hitherto, current therapies were unable to
eradicate the virus. Moreover, the gradual weakening of infected
patients’ immune system sets important barriers regarding
effective disease monitoring [5]. With the advent of antiretroviral
therapy in the mid-1990s, patients’ life expectancy and quality of
life increased, thus leading to an ever-increasing cost of HIV
infection, attributed to the high cost of antiretroviral therapy and
to the specialized inpatient and outpatient health services
required for the monitoring of HIV-positive patients [6,7].
As a result, health care managers, policymakers, and practi-
tioners need to have up-to-date data on costs, especially when
considering a country such as Greece where austerity measures
have been undertaken, reducing the available resources. There-
fore, funds’ allocation needs to be more effective, respon-
ding to patients’ needs, especially when it involves a disease
with so many particularities [8]. The growing number of HIV
seropositives, antiretroviral therapy, and the chronic nature
of HIV infection itself generate the constant rise in expendi-
tures and lead current research to focus on the cost estimationociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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disease [9].
The present study aimed at estimating all health care resources
consumed by HIV-infected patients in Greece, on an annual basis,
as well as their respective costs. Themain objective of this analysis
was to provide an up-to-date estimation of HIV-infection’s direct
cost in Greece to redraw and improve the health services provided
to this particularly vulnerable patient population.Methods
Research Design
A retrospective study was performed to estimate the direct cost
of HIV infection. In Greece, HIV patients are exclusively moni-
tored by HIV specialists in infectious diseases units of public
hospitals. Therefore, all costs associated with HIV management
involve health resources consumed in a public hospital setting.
Direct medical costs and antiretroviral therapy costs were
assessed from a third-party payer perspective.
Study Participants/Patients
The sample was composed of subjects monitored in the Infectious
Diseases Unit of a general hospital in Athens. Patients aged 18
years or older, followed in the HIV special unit from July 2, 2012, to
July 2, 2013, were included in the study. Out of 489 patients
monitored in the unit, 447 ﬁnally met the inclusion criteria
because clinical data within the aforementioned period were not
available for 42 patients. All ethical requirements were met, and
each participant returned his or her written informed consent.
Data were obtained from their medical records, and medical
conﬁdentiality was preserved throughout the course of the survey.
Patients were stratiﬁed according to the CD4 T-lymphocyte
count at the beginning of the study period. Three main cell-count
categories emerged in accordance with the Centers for Disease
Control and Prevention classiﬁcation system for HIV infection.
The ﬁrst category included patients with 500 or more CD4 cells/μl,
the second one patients with 200 to 499 cells/μl, and ﬁnally the
third one patients with less than 200 cells/μl.
Data Collection
The following data were collected through medical records:
demographic and clinical characteristics (age, nationality, date
of initial diagnosis, sex, mode of transmission, HIV RNA levels,
and CD4 T-lymphocyte count), outpatient visits, hospitalizations,
laboratory tests and imaging studies, as well as antiretroviral
drugs. Outpatient visits only included visits to specialist physi-
cians because in Greece, HIV-infected patients are exclusively
monitored by specialists and not by general practitioners. Hospi-
talizations comprised all admissions related to HIV infection,
those recorded in the intensive care unit included. Laboratory
investigation subsumed routine laboratory tests that were per-
formed twice a year (CD4 T-lymphocyte count, HIV RNA test, full
blood cell count, routine blood biochemistry) and any other test
patients were submitted to depending on their health status.
Finally, regarding pharmaceutical treatment, only antiretroviral
therapy was taken into account.
Cost Estimation
The analysis was performed from a third-party payer perspective
and involved all costs related to HIV patients’ follow-up. Expen-
ditures were divided into two main categories: medication costs
and costs associated with health care services that HIV-infected
patients received in the hospital setting. To calculate these costs,the frequency of each treatment or health service used was
multiplied by the associated charge. All costs were evaluated in
euros and in accordance with the latest Greek price bulletin of
August 2013 [10].
Drug costs included the cost of antiretroviral drugs used to
treat HIV infection and did not incorporate prophylactic or other
medications that HIV-infected patients may have been pre-
scribed. All prescribed treatments were available from the med-
ical records. Cost calculations were based on reimbursable prices.
These prices were then multiplied by the amount of drugs that
patients received during the reporting year [11].
Costs associated with health care services provided through
the Specialized Unit included costs for outpatient visits, hospital-
ization, laboratory investigation, and imaging tests. Outpatient
visits concerned regular HIV clinic visits. Hospitalization costs
were obtained via the ofﬁcial Greek price list, based on admission
diagnosis, according to the International Statistical Classiﬁcation of
Diseases, 10th Revision, and reported on patient's medical record
[12]. The cost of laboratory investigation, including all laboratory
tests and any other test that HIV-infected patients may have
been submitted to, was calculated as cost per test per patient [10].Results
Patient Characteristics
In a total of 447 patients, 383 (86%) were men and 64 (14%) were
women, of which the great majority was of Greek nationality (403
patients), whereas other patients were from Africa, Eastern
Europe, Western Europe, Middle East, and Central and South
America, in descending order. The mean age of participants was
45  11.86 years. Taking into account the age classiﬁcation, most
patients were from the 36- to 50-year-old age group (N ¼ 203,
45%), followed by the 51- to 65-year-old age group (N ¼ 115, 26%).
Nearly 106 patients (24%) belonged to the 18- to 35-year-old age
group and ﬁnally only 23 (5%) were aged 66 years or older. For the
mode of HIV transmission, ﬁve main categories were distin-
guished: homosexual transmission (being the most representa-
tive, as for 273 [61%] patients, the virus was transmitted through
this mode), heterosexual contact (N ¼ 117, 26%), intravenous drug
users (N ¼ 14, 3%), homosexual intravenous drug users (N ¼ 5,
1%), and unknown transmission route (N ¼ 38, 9%) (Table 1).
As mentioned above, patients were stratiﬁed into three cate-
gories according to the Centers for Disease Control and Preven-
tion classiﬁcation system for HIV infection, based on the CD4
T-lymphocyte count. The CD4 count considered to classify the
participants was the most recent to the starting date of the survey.
The great majority of the cohort (N ¼ 288, 64%) was classiﬁed in
the ﬁrst category, including patients with 500 or more cells/μl.
Patients having between 200-499 cells/μL represented 29% of the
sample (128 patients), while 31 participants, counting less than 200
cells/μL were included in the third category, representing 7% of the
sample. The mean CD4 T-lymphocyte count, overall health states,
was 638 cells/μl (Table 1).
Health Care Utilization
Health care utilization showed that, some exceptions aside,
patients with lower CD4 levels presented higher use of health
services both in routine laboratory tests, such as viral load tests
or CD4 count tests, and in all other tests that patients may have
been submitted to. The same pattern was held for outpatient
visits. Patients who counted lower CD4 levels, being more prone
to infectious diseases, presented a higher percentage of hospital
admissions. Patients with lower CD4 levels also suggest a higher
percentage of hospital admissions because they are more prone
Table 1 – Demographic and clinical characteristics
of HIV-infected patients.
Characteristic N ¼ 447 Percentage
(%)
Sex
Male 383 86
Female 64 14
Age category (y)
18–35 106 24
36–50 203 45
51–65 115 26
Z66 23 5
Age (y), mean  SD 45  12 –
Nationality
Greek 403 90
African 16 4
Eastern European 15 3
Western European 8 2
Middle Eastern 4 1
Central and South American 1 0
CD4 category (cells/μl)
Z500 288 64
200–499 128 29
o200 31 7
CD4 count, cells/μl, mean  SD 638  315 –
Mode of transmission
Homosexual contact 273 61
Heterosexual contact 117 26
IDU 14 3
IDU þ homosexual contact 5 1
Unknown 38 9
IDU, intravenous drug user.
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cells/μl, 71 hospital admissions/100 patients were observed, in
contrast to participants stratiﬁed in the ﬁrst category (Z500 cells/
μl) and the second category (200–400 cells/μl), presenting 10 and
12 hospital admissions/100 patients, respectively. Hence, 61% and
59% more hospital admissions were attributed to patients with
less than 200 cells/μl compared with those with more than 500
cells/μl and those presenting between 200 and 499 cells/μl,
respectively. Health care utilization by CD4 cell-count stratum
is presented in Table 2.
Cost Calculations
Total costs
Total direct costs including outpatient visits, hospitalization,
laboratory/imaging tests, and drug costs were estimated atTable 2 – Health care utilization by HIV patients categori
CD4
count
(cells/μl)
Mean/CD4 cate
Viral load
tests
(P ¼ NS)
CD4 count
tests
(P ¼ NS)
Complete blood
cell count
(P o 0.05)
Bioc
(P
Z500 2.2 2.3 2.6
200–499 2.3 2.5 3.0
o200 2.6 2.6 3.2
Overall 2.3 2.4 2.7
NS, not signiﬁcant.€6860  €4699 per patient on an annual basis regardless of the
CD4 levels. A trend toward higher total cost was noticed when
moving from the ﬁrst category (Z500 CD4 cells/ml) to the third
category (o200 cells/ml), even though not statistically signiﬁcant.
The cost of antiretroviral therapy was estimated at €5741.11 and
represented 83.7% of the total direct costs. Costs of both health
care services provided and antiretroviral treatment increased as
the CD4 levels decreased. More speciﬁcally, the CD4 count
appeared to particularly correlate with laboratory/imaging tests’
and hospitalization’s costs (P o 0.05). All costs were estimated in
2013 euros, as presented in Table 3.
Antiretroviral therapy
Out of 447 patients, 81 were treatment-naive, having never
received any antiretroviral therapy during the considered year
or before. Among 366 experienced patients, 26 switched therapy
within the aforesaid time horizon. Total annual expenditure of
antiretroviral therapy per patient, regardless of the CD4 count,
was calculated at €5741, representing 83.7% of the total
direct costs.
Cost of health care services provided in the hospital setting
The cost of health care services provided in the hospital included
the cost of intensive care unit and non–intensive care unit
hospitalizations, laboratory/imaging tests, as well as outpatient
visits to HIV specialist physicians and was estimated at €1118 
€470 regardless of the CD4 count. Laboratory/imaging tests
represented the largest part of this cost category and were
assessed at €924, followed by hospitalization (€160.31) and out-
patient visits (€34).Discussion
In a time when many countries are confronted with social and
economic turbulence, resources are becoming even scarcer; thus,
the need for effective organization and management of health
services, based on the population’s needs, is compelling. To
achieve these objectives, the main tools used are costing meth-
ods, which enable policymakers to take decisions according to
patients’ requirements. The estimation of the economic burden
of diseases is therefore the ﬁrst step in planning specialized
health services. The present study seems to be the ﬁrst over the
last 15 years that attempts to estimate the health resources
consumed by HIV-infected patients in Greece and their associ-
ated costs. Therefore, it cannot be compared with previous
studies performed in the same health care setting. Several
surveys, however, have been undertaken in Europe and the
United States.
Such studies appear to have great importance, especially
when considering chronic diseases that exhibit several diversitieszed by CD4 cell count.
gory Hospital
admissions per
100 patients
(P o 0.05)
hemical
tests
o 0.05)
Other
laboratory
tests (P ¼ NS)
Outpatient
visits
(P ¼ NS)
2.5 2.1 2.4 10
2.8 2.0 2.4 12
3.2 2.5 2.7 71
2.6 2.1 2.6 –
Table 3 – Mean costs per HIV-infected patient per year.
CD4 count
(cells/μl)
Mean cost (€)/patient/y Total
(P ¼ NS)
Paraclinical tests
(P o 0.05)
Outpatient visits
(P ¼ NS)
Hospitalization
(P o 0.05)
Antiretroviral therapy
(P ¼ NS)
Z500 848.48 32.19 61.23 5094.81 6066.76
200–499 917.12 34.74 63.14 5820.83 6857.70
o200 1005.77 36.25 356.57 6307.71 7654.31
Overall 923.79 34.39 160.31 5741.11 6859.60
NS, not signiﬁcant.
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assessed the annual direct cost of HIV infection per patient in
Greece and, furthermore, compared the costs attributed to differ-
ent health states. Findings suggested that both total direct cost
and partial costs associated with several resources consumed
increased as the count of CD4 T lymphocytes decrease. Most
patients of the sample, however, seemed to have more than 500
cells/μl, indicating adequate follow-up. Regardless of the health
state considered, the total direct cost was calculated at €6860 per
patient per year, while the largest part was attributed to anti-
retroviral therapy, estimated at €5741 and representing 83.7% of
the total cost.
The reported results of this survey seemed to be in line with
other published studies conducted in Europe, Canada, and the
United States. Nevertheless, any differences observed among
these studies were due to unlike methodological approaches,
and to diversions regarding the variables considered, in order to
assess the cost of illness.
Krentz and Gill [13] studied the direct costs of newly diag-
nosed patients with less than 350 CD4 cells per mm3 in Southern
Alberta in Canada from 1995 to 2010. The cost of treatment for
these individuals was $17.028 per year, while for early diagnosed
patients the cost was $10,968 per year (expressed in Canadian
dollars adjusted to 2009). The direct cost estimation included the
cost of hospitalization, outpatient visits, laboratory tests, and
drug treatment (including non- and antiretroviral therapy).
Despite the fact that by providing antiretroviral treatment, the
CD4 T-lymphocyte levels gradually increased over time, the cost
still remained high, with hospitalization costs representing 64%
of total expenditures [13]. The same authors [14] conducted, from
2000 to 2008, a study in which they compared the health care
costs between local and immigrant HIV patients of Southern
Alberta. Drug, inpatient, and outpatient costs were included, and
ﬁnal results were expressed in mean costs per patient per month
in 2009 Canadian dollars. Findings showed no statistically sig-
niﬁcant difference between Canadian and foreign patients, with
direct cost calculated at $1174 and $1067, respectively.
Hutchinson et al. [15] assessed the cost of HIV infection in the
United States focusing on racial and ethnic differences. This
study, beyond direct costs (hospitalization, non- and antiretro-
viral therapy, laboratory tests, outpatient visits), estimated the
productivity loss due to mortality. Patients diagnosed early and
under antiretroviral treatment presented higher life expectancy
(24.4 years), and lifetime cost was computed at $361,944. How-
ever, patients who were not prescribed any antiretroviral agents
had an average life expectancy of 12.4 years and estimated
lifetime direct costs of $145,218 [15].
Several European studies of HIV infection cost estimation
have been conducted over the last few years. In Sweden,
Ghatnekar et al. [16] estimated the cost of antiretroviral drugs,
laboratory tests, outpatient visits, and hospitalization. The study
included data from 285 patients, monitored in the Sahlgrenska
University Hospital, from 2000 to 2005. The average cost perpatient and per month was €1069, 51% of which was attributed to
antiretroviral therapy, 22% to hospitalization, 19% to outpatient
visits, and 7% to laboratory tests. In addition, it was observed that
all partial costs, besides the cost of antiretroviral therapy,
increased with the decrease in the number of CD4 T lymphocytes
[16]. Colin et al. [17] assessed the cost of managing HIV infection
in France, using data from French hospital database and includ-
ing 50% of HIV patients from 2003 to 2005. The study evaluated
the cost of antiviral agents, antiparasitic drugs, antimycobacterial
agents, and hospitalizations. The mean health care costs per
patient-year seemed to decrease as CD4 cell-count increased and
varied from €34,286 to €12,361 [17]. In Germany, Mostardt et al.
[18] performed an 18-month prospective study estimating the
cost of HIV infection from 2006 to 2009. About 518 patients from
17 ambulatory care centers were included. The study assessed
the annual health care cost from the societal and statutory
perspectives. The average annual health care costs were €23,298
per patient when the analysis was performed from the ﬁrst
perspective and €19,103 when the analysis was performed from
the second perspective. As anticipated, most of the estimated
cost was associated with antiretroviral therapy [18].
The aforementioned surveys present some patterns that are
alike for most of them but also several differences. The results of
the studies conducted denoted that the deﬁciency of the immune
system and therefore the decrease in CD4 cell count resulted in
higher costs. In addition, the largest part of total direct cost of HIV
infection was in all cases attributed to antiretroviral therapy.
Indeed, the cost of providing medical care to HIV patients has
deﬁnitely increased since the introduction of highly active anti-
retroviral therapy [19,20]. Nevertheless, cost estimations also
presented great differences and heterogeneities. They differed in
the nature of the study itself, the sample considered, and espe-
cially the characteristics of patients, the country’s health system,
the components of the estimated cost, as well as unit costs [21]. As
a matter of fact, the aforestated studies used a different approach
for the estimation of HIV infection’s direct cost. As a result,
comparing the ﬁndings of the different studies seems quite
challenging; however, some general conclusions can certainly be
drawn [22,23]. The present survey seems to be in line with the
European studies regarding the overall results; nonetheless, some
differences can be distinguished. Our ﬁndings suggested that
83.7% of the direct cost was due to antiretroviral therapy and that
only 2.3% was attributed to hospitalization expenditures. In the
studies conducted in Sweden, France, and Germany, the results
seemed to be comparable because in all cases, hospitalization
rates seemed to increase as the CD4 levels decreased, and the
highest cost rates were also attributed to drugs. Especially in the
case of Germany, it was found that 89% of the direct cost was due
to antiretroviral therapy, which is very close to our results.
However, hospitalization costs were about three times higher than
our estimations, representing 7% of total direct cost. Therefore,
such divergences could be considered consequences of the pre-
viously mentioned methodological differences.
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retrospective documentation of health care resources used by
patients, which could potentially imply lack of evidence. In
addition, the survey did not include indirect and hidden costs
of the disease, as well as some variables such as coinfections,
which deﬁnitely have an impact in both clinical and economic
terms. The analysis was performed from a third-party payer
perspective, and therefore the study does not reﬂect market
prices and indirect costs as mentioned above. Finally, results of
the present study eventually cannot be generalized to the overall
population; however, they can be regarded as representative of
the cost that HIV infection generates in Greece. Moreover, it is the
ﬁrst study over the last 15 years undertaken in Greece; thus, it
can be used as a reference for further studies, not only for Greece
but also for different countries and health care systems.
In summary, the direct cost of HIV infection seems to be quite
high considering its chronic character. The total cost appears to
increase, in line with the immune system’s deﬁciency, as
patients become more prone to opportunistic infections. The
methodology of the present study enables the extrapolation of
results to other countries because the care process of HIV
infection, subsequent health resources consumed, and different
types of expenses are based on current guidelines for HIV
management. Therefore, the outcomes of the cost analysis
performed can be comparable to those of different health care
systems, and could also be used as a reference for further studies.
Finally, efforts should be focused on the enhancement of pre-
ventions and early diagnosis. The reinforcement of such health
policies could signiﬁcantly reduce costs of HIV infection by
controlling the spread and life cycle of the virus.
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